Outcomes following Serial Intragastric Balloon Therapy for Obesity and Nonalcoholic Fatty Liver Disease in a Single Centre

Table 1

Baseline characteristics.

Clinical parameter	Patient numbers
Age (years), mean ± SD	47.1 (12.2)
Sex	M 39 (29%), F 96 (71%)
Ethnicity
(i) Caucasian	89 (66%)
(ii) Black	27 (20%)
(iii) Asian (Indian)	2 (2%)
(iv) Asian (oriental)	2 (2%)
(v) Latino	6 (4%)
(vi) Mixed	3 (2%)
Diabetes	39/134 (29%)
Other MetSy features	60/134 (45%)
Taking ACE-inhibitor medication	94/133 (71%)
Fasting BSL (mmol/L), mean ± SD	6.0 ± 2.7
Weight (kg), mean ± SD	117.9 ± 22.0
BMI (kg/m^2), mean ± SD	41.7 ± 6.6
Waist circumference (cm), mean ± SD	124.2 ± 13.6
Fasting cholesterol (mmol/L), mean ± SD	4.8 ± 1.4
Fasting LDL (mmol/L), mean ± SD	2.7 ± 1.1
Fasting HDL (mmol/L), mean ± SD	1.2 ± 0.3
Fasting triglycerides (mmol/L), mean ± SD	1.8 ± 1.0
Fasting insulin (mIU/L), mean ± SD	136.0 ± 169.0
HOMA-IR , median (range	3.6 (2.1–5.9)
ALT (IU/L), mean ± SD	38.9 ± 30.6
AST (IU/L), mean ± SD	35.1 ± 25.2
GGT (IU/L), mean ± SD	62.6 ± 74.9
Fib-4 score , mean ± SD	1.5 ± 0.7
Period of 1st IGB placement (months), mean ± SD	5.8 ± 1.7
Total number of balloons	One = 135, two = 48, three =20

5–75% interquartile ranges expressed.